News
In addition to Scotiabank, Biogen also received a Buy from H.C. Wainwright’s Andrew Fein in a report issued today. However, on the same day, Truist Financial maintained a Hold rating on Biogen (NASDAQ ...
In a report released today, Jay Olson from Oppenheimer reiterated a Buy rating on Biogen, with a price target of $205.00. The company’s shares closed today at $128.00. Take advantage of TipRanks ...
Major indices delivered a mixed performance on Thursday after Donald Trump's newly announced chip tariffs included broad ...
NasdaqGS:BIIB 1 Year Share Price vs Fair Value Explore Biogen's Fair Values from the Community and select yours ...
Amid a cautious outlook, Biogen has presented new data at the Alzheimer’s Association International Conference (AAIC) 2025, demonstrating that investigational Leqembi 360 mg subcutaneous maintenance ...
We came across a bullish thesis on Biogen Inc. on r/Valueinvesting subreddit by U/Lobyous. In this article, we will summarize ...
Biogen Inc. (NASDAQ:BIIB) is one of the top cheap pharmaceutical stocks to buy now. BofA lowered the firm’s price target on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results